Peter Andersen

Peter Andersen

Professor of Neurology and Senior Neurologist

Professor Andersen obtained his medical degree from Copenhagen University and specialised in neurology. In the same year he also completed his doctoral thesis on SOD1 genetics and pathology in ALS. After this, he moved for one year to  MGH/Harvard Medical School for his postdoctoral research. In 1992, he established the multidisciplinary Clinical Care ALS Team at Umeå University Hospital that cares for patients from northern Sweden and also sees second-opnion patients from other parts of Sweden and abroad. His research focuses on genetics, free radicals and SOD1 protein-prion research. He also has an interest in biomarker research. He has been a senior neurologist since 2001 and was appointed as a Professor in Neurology in 2010. He has won various prizes including the Charcot Prize (2000) and the Wallenberg Clinical Scholar 2016—2020 for focused ALS Research.

Connect
Connect trials
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.

Read more
Active
Phase iii

ALXN1210-ALS-308 trial

Industry trial

This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.

Read more
Active
Phase iii

VALOR study

Industry trial

Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.

Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

Read more